$682.74
0.66% today
Nasdaq, Jan 30, 07:13 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$687.27
-15.32 2.18% 1M
-389.92 36.20% 6M
-25.06 3.52% YTD
-268.53 28.09% 1Y
+78.68 12.93% 3Y
+348.02 102.59% 5Y
+272.63 65.75% 10Y
Nasdaq, Closing price Wed, Jan 29 2025
+0.94 0.14%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $75.52b
Enterprise Value $68.43b
P/E (TTM) P/E ratio 17.01
EV/FCF (TTM) EV/FCF 19.89
EV/Sales (TTM) EV/Sales 4.94
P/S ratio (TTM) P/S ratio 5.45
P/B ratio (TTM) P/B ratio 2.58
Revenue growth (TTM) Revenue growth 5.72%
Revenue (TTM) Revenue $13.85b
EBIT (operating result TTM) EBIT $4.14b
Free Cash Flow (TTM) Free Cash Flow $3.44b
Cash position $9.80b
EPS (TTM) EPS $40.41
P/E forward 17.36
P/S forward 5.33
EV/Sales forward 4.83
Short interest 2.03%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Regeneron Pharmaceuticals forecast:

19x Buy
63%
10x Hold
33%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
63%
Hold
33%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13,847 13,847
6% 6%
100%
- Direct Costs 2,391 2,391
13% 13%
17%
11,456 11,456
4% 4%
83%
- Selling and Administrative Expenses 2,435 2,435
14% 14%
18%
- Research and Development Expense 4,414 4,414
13% 13%
32%
4,608 4,608
7% 7%
33%
- Depreciation and Amortization 470 470
15% 15%
3%
EBIT (Operating Income) EBIT 4,138 4,138
9% 9%
30%
Net Profit 4,655 4,655
17% 17%
34%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
one day ago
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of long-term stockholders following a class action complaint that was filed against Regeneron on January 7, 2025 with a Class Period from November 2, 2023 to October 30, 202...
Neutral
PRNewsWire
3 days ago
NEW YORK , Jan. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 13,450
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today